Sonal Mahajan

Sonal Mahajan

Auto-generated profile, based on publicly available information

Sonal Mahajan

Sanford Children’s Health Research Center, Sanford Burnham Prebys, La Jolla, CA, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 September 2023 in Journal of Inherited Metabolic Disease
Verified
Journal Article
Open access
FCFrancisco del Caño-Ochoa
Francisco del Caño-Ochoa
BNBobby G. Ng
Bobby G. Ng
ARAntonio Rubio‐Del‐Campo
Antonio Rubio‐Del‐Campo
SMSonal Mahajan
Sonal Mahajan
MWMatthew Wilson
Matthew Wilson
SRSantiago Ramon-Maiques
Santiago Ramon-Maiques
CAD is a large, 2225 amino acid multienzymatic protein required for de novo pyrimidine biosynthesis. Pathological CAD variants cause a developmental and epileptic encephalopathy which is highly responsive to uridine supplements. CAD deficiency is difficult to diagnose because symptoms are nonspecific, there is no biomarker, and the protein has over 1000 known variants. To improve diagnosis, we assessed the pathogenicity of 20 unreported missense CAD variants using a growth complementation assay that identified 11 pathogenic variants in seven affected individuals; they would benefit from uridine treatment. We also tested nine variants previously reported as pathogenic and confirmed the damaging effect of seven. However, we reclassified two variants as likely benign based on our assay, which is consistent with their long‐term follow‐up with uridine. We found that several computational methods are unreliable predictors of pathogenic CAD variants, so we extended the functional assay results by studying the impact of pathogenic variants at the protein level. We focused on CAD's dihydroorotase (DHO) domain because it accumulates the largest density of damaging missense changes. The atomic‐resolution structures of eight DHO pathogenic variants, combined with functional and molecular dynamics analyses, provided a comprehensive structural and functional understanding of the activity, stability, and oligomerization of CAD's DHO domain. Combining our functional and protein structural analysis can help refine clinical diagnostic workflow for CAD variants in the genomics era.

1 September 2017 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
SMSonal Mahajan
Sonal Mahajan
AKAasawari Khairnar
Aasawari Khairnar
RBRitika Bishnoi
Ritika Bishnoi
TRT.N.C. Ramya
T.N.C. Ramya

10 November 2022 in Journal of Medical Genetics
Verified
Journal Article
Closed access
PDF file
SMSonal Mahajan
Sonal Mahajan
BNBobby George Ng
Bobby George Ng
LALama AlAbdi
Lama AlAbdi
PEPaul Daniel James Earnest
Paul Daniel James Earnest
PSPaulina Sosicka
Paulina Sosicka
HFHudson Freeze
Hudson Freeze
Background: Enzymes of the Golgi implicated in N-glycan processing are critical for brain development, and defects in many are defined as congenital disorders of glycosylation (CDG). Involvement of the Golgi mannosidase, MAN2A2 has not been identified previously as causing glycosylation defects. Methods: Exome sequencing of affected individuals was performed with Sanger sequencing of the MAN2A2 transcript to confirm the variant. N-glycans were analysed in patient-derived lymphoblasts to determine the functional effects of the variant. A cell-based complementation assay was designed to assess the pathogenicity of identified variants using MAN2A1/MAN2A2 double knock out HEK293 cell lines. Results: We identified a multiplex consanguineous family with a homozygous truncating variant p.Val1101Ter in MAN2A2. Lymphoblasts from two affected brothers carrying the same truncating variant showed decreases in complex N-glycans and accumulation of hybrid N-glycans. On testing of this variant in the developed complementation assay, we see the complete lack of complex N-glycans. Conclusion: Our findings show that pathogenic variants in MAN2A2 cause a novel autosomal recessive CDG with neurological involvement and facial dysmorphism. Here, we also present the development of a cell-based complementation assay to assess the pathogenicity of MAN2A2 variants, which can also be extended to MAN2A1 variants for future diagnosis.

14 April 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
SMSonal Mahajan
Sonal Mahajan
SASara Ancel
Sara Ancel
GAGiuliana Ascone
Giuliana Ascone
RKRajdeep Kaur
Rajdeep Kaur
JTJuancarlos Torres
Juancarlos Torres
HFHudson Freeze
Hudson Freeze
Summary: Saul-Wilson syndrome (SWS) is a skeletal dysplasia characterized by primordial dwarfism and progeroid features caused by a recurrent dominant COG4 variant (p.G516R). We previously showed that this mutation accelerates Golgi retrograde trafficking and disrupts glycosylation of the proteoglycan decorin, while zebrafish models revealed defects in chondrocyte elongation and intercalation. We have also shown that the SW1353 chondrosarcoma cells carrying the SWS variant exhibit reduced secretion of extracellular matrix (ECM) components. While these results indicate a critical function of COG4 in Golgi processing, the developmental process leading to skeletal dysplasia in SWS patients remains unknown. Here, we generated patient-derived iPSC cartilage organoids (SWS organoids), modeling early human chondrogenesis. SWS organoids failed to produce cartilage structures and displayed poor expression of chondrogenic markers. Time-course RNA-seq analysis of the chondrogenic process revealed reduced activation of gene networks involved in skeletal development, ECM organization, ossification, and glycosaminoglycan metabolism. Spatial multiomic analysis of protein and glycosylation by CODEX and GLYPH imaging revealed an altered chondrogenic trajectory, persistence of mesenchymal states, global glycosylation changes, and reduced deposition of chondroitin sulfate proteoglycans. These results indicate that the COG4 mutation disrupts ECM glycosylation and chondrogenic commitment, and that SWS organoids model early defects in cartilage formation underlies impaired skeletal growth in SWS. Highlights: Patient iPSC-derived cartilage organoids model development defects in Saul–Wilson syndrome SWS organoids show defective extracellular matrix deposition and attenuated chondrogenic gene expression Glycan profiling reveals global glycosylation defects and deficient proteoglycan GAG chains An early developmental impairment in chondrogenesis alters skeletal formation in Saul–Wilson syndrome